This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Why Zoetis (ZTS) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw Zoetis (ZTS) settling at $165.69, representing a -0.1% change from its previous close.
Zoetis (ZTS) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Company News for Feb 14, 2024
by Zacks Equity Research
Companies in The News Are: ZTS,MAR,ECL,HAS
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
by Zacks Equity Research
Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.
Compared to Estimates, Zoetis (ZTS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) Q4 Earnings Lag Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of -6.77% and 1.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Drug, Biotech Stocks' Q4 Earnings Due on Feb 13: BIIB, ZTS & INCY
by Zacks Equity Research
Let's take a look at three biotech/drug companies, BIIB, ZTS, and INCY, slated to release quarterly results on Feb 13.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the fourth quarter of 2023, partially offset by declining livestock product sales.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Ahead of Zoetis (ZTS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
GRFS or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Should You Invest in the VanEck Agribusiness ETF (MOO)?
by Zacks Equity Research
Sector ETF report for MOO
The Zacks Analyst Blog Highlights Invitation Homes, Choice Hotels International, Zoetis and Owens Corning
by Zacks Equity Research
Invitation Homes, Choice Hotels International, Zoetis and Owens Corning are part of the Zacks top Analyst Blog.
4 Stocks to Watch That Recently Declared Dividend Hikes
by Ritujay Ghosh
Invitation Homes Inc. (INVH), Choice Hotels International, Inc. (CHH), Zoetis Inc. (ZTS) and Owens Corning (OC) recently announced dividend hikes.